FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:87-94 January 11, 2001 Number 2 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background 1,4-Butanediol is an industrial solvent that, when ingested, is converted to -hydroxybutyrate, a drug of abuse with depressant effects, primarily on the central nervous system. After reports of toxic effects of -hydroxybutyrate and its resultant regulation by the federal government, 1,4-butanediol and -butyrolactone, another precursor of -hydroxybutyrate and an industrial solvent, began to be marketed as dietary supplements. We investigated reports of toxic effects due to the ingestion of 1,4-butanediol and reviewed the related health risks.

Methods From June 1999 through December 1999, we identified cases of toxic effects of 1,4-butanediol involving patients who presented to our emergency departments with a clinical syndrome suggesting toxic effects of -hydroxybutyrate and a history of ingesting 1,4-butanediol and patients identified through public health officials and family members. We used gas chromatography–mass spectrometry to measure 1,4-butanediol or its metabolite, -hydroxybutyrate, in urine, serum, or blood.

Results We identified nine episodes of toxic effects in eight patients who had ingested 1,4-butanediol recreationally, to enhance bodybuilding, or to treat depression or insomnia. One patient presented twice with toxic effects and had withdrawal symptoms after her second presentation. Clinical findings and adverse events included vomiting, urinary and fecal incontinence, agitation, combativeness, a labile level of consciousness, respiratory depression, and death. No additional intoxicants were identified in six patients, including the two who died. The doses of 1,4-butanediol ingested ranged from 5.4 to 20 g in the patients who died and ranged from 1 to 14 g in the nonfatal cases. In some cases there was evidence of addiction and withdrawal.

Conclusions The health risks of 1,4-butanediol are similar to those of its counterparts, -hydroxybutyrate and -butyrolactone. These include acute toxic effects, which may be fatal, and addiction and withdrawal.

Source Information

From the Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis (D.L.Z., S.W.S.); the Office of the Travis County Medical Examiner, Austin, Tex. (J.R.M., B.J.H., E.A.P.); and Broward General Medical Center, Nova Southeastern University, Fort Lauderdale, Fla. (J.S.).

Address reprint requests to Dr. Smith at the Department of Emergency Medicine, Hennepin County Medical Center, 701 Park Ave., Minneapolis, MN 55415-1829, or to Dr. Zvosec at dzvosec{at}hotmail.com.

Full Text of this Article

This article has been cited by other articles:

• Wood, D.M., Warren-Gash, C., Ashraf, T., Greene, S.L., Shather, Z., Trivedy, C., Clarke, S., Ramsey, J., Holt, D.W., Dargan, P.I. (2008). Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 101: 23-29 [Abstract] [Full Text]  
• Wang, Q., Morris, M. E. (2007). Flavonoids Modulate Monocarboxylate Transporter-1-Mediated Transport of {gamma}-Hydroxybutyrate in Vitro and in Vivo. Drug Metab. Dispos. 35: 201-208 [Abstract] [Full Text]  
• QUANG, L. S, COLOMBO, G., LOBINA, C., MACCIONI, P., ORRU`, A., GESSA, G. L., MAHER, T. J, CARAI, M. A.M (2006). Evaluation for the Withdrawal Syndrome from {gamma}-Hydroxybutyric Acid (GHB), {gamma}-Butyrolactone (GBL), and 1,4-Butanediol (1,4-BD) in Different Rat Lines.. Ann. N. Y. Acad. Sci. 1074: 545-558 [Abstract] [Full Text]  
• Wang, Q., Darling, I. M., Morris, M. E. (2006). Transport of {gamma}-Hydroxybutyrate in Rat Kidney Membrane Vesicles: Role of Monocarboxylate Transporters. J. Pharmacol. Exp. Ther. 318: 751-761 [Abstract] [Full Text]  
• Snead, O. C., Gibson, K. M. (2005). {gamma}-Hydroxybutyric Acid. NEJM 352: 2721-2732 [Full Text]  
• Morris, M. E., Hu, K., Wang, Q. (2005). Renal Clearance of {gamma}-Hydroxybutyric Acid in Rats: Increasing Renal Elimination as a Detoxification Strategy. J. Pharmacol. Exp. Ther. 313: 1194-1202 [Abstract] [Full Text]  
• Gonzalez, A., Nutt, D. J. (2005). Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 19: 195-204 [Abstract]  
• QUANG, L. S., DESAI, M. C., SHANNON, M. W., WOOLF, A. D., MAHER, T. J. (2004). 4-Methylpyrazole Decreases 1,4-Butanediol Toxicity by Blocking Its in Vivo Biotransformation to {gamma}-Hydroxybutyric Acid. Ann. N. Y. Acad. Sci. 1025: 528-537 [Abstract] [Full Text]  
• Bhattacharya, I., Boje, K. M. K. (2004). GHB ({gamma}-Hydroxybutyrate) Carrier-Mediated Transport across the Blood-Brain Barrier. J. Pharmacol. Exp. Ther. 311: 92-98 [Abstract] [Full Text]  
• Brush, D. E., Bird, S. B., Boyer, E. W. (2004). {gamma}-Hydroxybutyrate Use in Older Adults. ANN INTERN MED 140: W-70-W-71 [Full Text]  
• Varela, M, Nogue, S, Oros, M, Miro, OŇ (2004). Gamma hydroxybutirate use for sexual assault. Emerg. Med. J. 21: 255-256 [Abstract] [Full Text]  
• Tancredi, D. N., Shannon, M. W. (2003). Case 30-2003 - A 21-Year-Old Man with Sudden Alteration of Mental Status. NEJM 349: 1267-1275 [Full Text]  
• Van Sassenbroeck, D. K., De Paepe, P., Belpaire, F. M., Buylaert, W. A. (2003). Characterization of the Pharmacokinetic and Pharmacodynamic Interaction between Gamma-Hydroxybutyrate and Ethanol in the Rat. Toxicol Sci 73: 270-278 [Abstract] [Full Text]  
• Chyka, P. A. (2003). Health Risks of Selected Performance-Enhancing Drugs. Journal of Pharmacy Practice 16: 37-44 [Abstract]  
• QUANG, L. S., DESAI, M. C., KRANER, J. C., SHANNON, M. W., WOOLF, A. D., MAHER, T. J. (2002). Enzyme and Receptor Antagonists for Preventing Toxicity from the Gamma-Hydroxybutyric Acid Precursor 1,4-Butanediol in CD-1 Mice. Ann. N. Y. Acad. Sci. 965: 461-472 [Abstract] [Full Text]  
• Boyer, E. W., Shannon, M., Hibberd, P. L. (2001). Web Sites with Misinformation about Illicit Drugs. NEJM 345: 469-471 [Full Text]  
• (2001). The Toxic Effects of 1,4-Butanediol. JWatch Emergency Med. 2001: 9-9 [Full Text]  
• (2001). Another Dietary Supplement, Another Drug of Abuse. JWatch Psychiatry 2001: 4-4 [Full Text]